FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965639726> ?p ?o ?g. }

• W1965639726 endingPage "e86692" @default.
• W1965639726 startingPage "e86692" @default.
• W1965639726 abstract "Efficacy of tumor necrosis factor alpha (TNF-α) blockers for treatment of ulcerative colitis that is unresponsive to conventional therapy is unclear due to recent studies yielding conflicting results.To assess the efficacy and safety of anti-TNF-α agents for treatment of ulcerative colitis patients who were intolerant or refractory to conventional medical therapy.Pubmed, Embase, and the Cochrane database were searched. Analysis was performed on randomized controlled trials that assessed anti-TNF-α therapy on ulcerative colitis patients that had previously failed therapy with corticosteroids and/or immunosuppressants. The primary outcome focused on was the frequency of patients that achieved clinical remission. Further trial outcomes of interest included rates of remission without patient use of corticosteroids during the trial, extent of mucosal healing, and the number of cases that resulted in colectomy and serious side effects.Eight trials from seven studies (n = 2122) met the inclusion criteria and were thus included during analysis. TNF-α blockers demonstrated clinical benefit as compared to placebo control as evidenced by an increased frequency of clinical remission (p<0.00001), steroid-free remission (p = 0.01), endoscopic remission (p<0.00001) and a decrease in frequency of colectomy (p = 0.03). No difference was found concerning serious side effects (p = 0.05). Three small trials (n = 57) comparing infliximab to corticosteroid treatment, showed no difference in frequency of clinical remission (p = 0.93), mucosal healing (p = 0.80), and requirement for a colectomy (p = 0.49). One trial compared infliximab to cyclosporine (n = 115), wherein no difference was found in terms of mucosal healing (p = 0.85), colectomy frequency (p = 0.60) and serious side effects (p = 0.23).TNF-α blockers are effective and safe therapies for the induction and maintenance of long-term remission and prevention of treatment by colectomy for patients with refractory ulcerative colitis where conventional treatment was previously ineffective. Furthermore, infliximab and cyclosporine were found to be comparable for treating acute severe steroid-refractory ulcerative colitis." @default.
• W1965639726 created "2016-06-24" @default.
• W1965639726 creator A5016653303 @default.
• W1965639726 creator A5021171895 @default.
• W1965639726 creator A5032866102 @default.
• W1965639726 creator A5041338087 @default.
• W1965639726 creator A5057648803 @default.
• W1965639726 creator A5060120199 @default.
• W1965639726 creator A5078767024 @default.
• W1965639726 date "2014-01-27" @default.
• W1965639726 modified "2023-10-17" @default.
• W1965639726 title "Tumor Necrosis Factor Alpha Blocking Agents as Treatment for Ulcerative Colitis Intolerant or Refractory to Conventional Medical Therapy: A Meta-Analysis" @default.
• W1965639726 cites W1530709545 @default.
• W1965639726 cites W1658971169 @default.
• W1965639726 cites W1694206139 @default.
• W1965639726 cites W1969387826 @default.
• W1965639726 cites W1977773914 @default.
• W1965639726 cites W1979434114 @default.
• W1965639726 cites W1984705525 @default.
• W1965639726 cites W1986215651 @default.
• W1965639726 cites W2009025779 @default.
• W1965639726 cites W2010193391 @default.
• W1965639726 cites W2010463972 @default.
• W1965639726 cites W2020640954 @default.
• W1965639726 cites W2028547258 @default.
• W1965639726 cites W2040401921 @default.
• W1965639726 cites W2064806601 @default.
• W1965639726 cites W2071644653 @default.
• W1965639726 cites W2089991488 @default.
• W1965639726 cites W2092863985 @default.
• W1965639726 cites W2093375795 @default.
• W1965639726 cites W2096256540 @default.
• W1965639726 cites W2102897127 @default.
• W1965639726 cites W2105246122 @default.
• W1965639726 cites W2111362292 @default.
• W1965639726 cites W2112768046 @default.
• W1965639726 cites W2146089966 @default.
• W1965639726 cites W2146692972 @default.
• W1965639726 cites W2156250460 @default.
• W1965639726 cites W2171297959 @default.
• W1965639726 cites W2182271449 @default.
• W1965639726 cites W4210972027 @default.
• W1965639726 cites W4362504902 @default.
• W1965639726 doi "https://doi.org/10.1371/journal.pone.0086692" @default.
• W1965639726 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3903567" @default.
• W1965639726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24475168" @default.
• W1965639726 hasPublicationYear "2014" @default.
• W1965639726 type Work @default.
• W1965639726 sameAs 1965639726 @default.
• W1965639726 citedByCount "44" @default.
• W1965639726 countsByYear W19656397262014 @default.
• W1965639726 countsByYear W19656397262015 @default.
• W1965639726 countsByYear W19656397262016 @default.
• W1965639726 countsByYear W19656397262017 @default.
• W1965639726 countsByYear W19656397262018 @default.
• W1965639726 countsByYear W19656397262019 @default.
• W1965639726 countsByYear W19656397262020 @default.
• W1965639726 countsByYear W19656397262021 @default.
• W1965639726 countsByYear W19656397262022 @default.
• W1965639726 countsByYear W19656397262023 @default.
• W1965639726 crossrefType "journal-article" @default.
• W1965639726 hasAuthorship W1965639726A5016653303 @default.
• W1965639726 hasAuthorship W1965639726A5021171895 @default.
• W1965639726 hasAuthorship W1965639726A5032866102 @default.
• W1965639726 hasAuthorship W1965639726A5041338087 @default.
• W1965639726 hasAuthorship W1965639726A5057648803 @default.
• W1965639726 hasAuthorship W1965639726A5060120199 @default.
• W1965639726 hasAuthorship W1965639726A5078767024 @default.
• W1965639726 hasBestOaLocation W19656397261 @default.
• W1965639726 hasConcept C121332964 @default.
• W1965639726 hasConcept C126322002 @default.
• W1965639726 hasConcept C141071460 @default.
• W1965639726 hasConcept C142424586 @default.
• W1965639726 hasConcept C142724271 @default.
• W1965639726 hasConcept C168563851 @default.
• W1965639726 hasConcept C17991360 @default.
• W1965639726 hasConcept C204787440 @default.
• W1965639726 hasConcept C27081682 @default.
• W1965639726 hasConcept C2776667177 @default.
• W1965639726 hasConcept C2777138892 @default.
• W1965639726 hasConcept C2779134260 @default.
• W1965639726 hasConcept C2780479503 @default.
• W1965639726 hasConcept C535046627 @default.
• W1965639726 hasConcept C71924100 @default.
• W1965639726 hasConcept C87355193 @default.
• W1965639726 hasConcept C90924648 @default.
• W1965639726 hasConceptScore W1965639726C121332964 @default.
• W1965639726 hasConceptScore W1965639726C126322002 @default.
• W1965639726 hasConceptScore W1965639726C141071460 @default.
• W1965639726 hasConceptScore W1965639726C142424586 @default.
• W1965639726 hasConceptScore W1965639726C142724271 @default.
• W1965639726 hasConceptScore W1965639726C168563851 @default.
• W1965639726 hasConceptScore W1965639726C17991360 @default.
• W1965639726 hasConceptScore W1965639726C204787440 @default.
• W1965639726 hasConceptScore W1965639726C27081682 @default.
• W1965639726 hasConceptScore W1965639726C2776667177 @default.
• W1965639726 hasConceptScore W1965639726C2777138892 @default.
• W1965639726 hasConceptScore W1965639726C2779134260 @default.

• next